MEGAN DUNCAN: Open Payments
NPI 1821442138 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,253 in 107 payments from 42 companies in 2025. Trend: 2023 $2,721 · 2024 $2,290 · 2025 $2,253
Food & beverage: $2,205Education: $48
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $183 |
| PFIZER INC. | 9 | $170 |
| Novartis Pharmaceuticals Corporation | 7 | $154 |
| GlaxoSmithKline, LLC. | 7 | $136 |
| Merck Sharp & Dohme LLC | 6 | $135 |
| Stemline Therapeutics Inc. | 5 | $119 |
| Daiichi Sankyo Inc. | 5 | $116 |
| Gilead Sciences, Inc. | 5 | $114 |
| Janssen Biotech, Inc. | 3 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $82 |
Products named: Orserdu, Trodelvy, KEYTRUDA, VENCLEXTA, FRUZAQLA, Lenvima, SCEMBLIX, IBRANCE.
Industry payments across GA — which companies pay providers there.
